David E. Tabor
AstraZeneca
19 Papers
15 Citations
David E. Tabor is an academic researcher from AstraZeneca. The author has contributed to research in topics: Staphylococcus aureus & Staphylococcus aureus alpha toxin. The author has an hindex of 10, co-authored 19 publications. Previous affiliations of David E. Tabor include MedImmune.
Chat about Author
Papers
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
Michelle L. Boland,Denise Oró,Kirstine S Tølbøl,Sebastian T. Thrane,Jens Nielsen,Taylor S. Cohen,David E. Tabor,Fiona Fernandes,Andrey Tovchigrechko,Sanne Skovgård Veidal,Paul Warrener,Bret R. Sellman,Jacob Jelsing,Michael Feigh,Niels Vrang,James L. Trevaskis,Henrik H. Hansen +16 more
TL;DR: Substitution of Primex with palm oil promotes a similar phenotype of biopsy-confirmed NASH in ob/ob and C57BL/6J mice, making GAN diet-induced obese mouse models suitable for characterizing novel NASH treatments.
102
Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17.
Bin Lu,Hui Liu,David E. Tabor,Andrey Tovchigrechko,Yanping Qi,Alexey Ruzin,Mark T. Esser,Hong Jin +7 more
TL;DR: Analysis of 1,146 RSV samples from 2015–2017 revealed a slight shift in prevalence from RSV A to B between the two seasons, indicating RSV surface glycoproteins are continuously evolving, and continued surveillance is important for the clinical evaluation of immunoprophylactic products.
70
Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893
David E. Tabor,Li Yu,Hoyin Mok,Christine Tkaczyk,Bret R. Sellman,Yuling Wu,Vaheh Oganesyan,Timothy Slidel,Hasan S. Jafri,Michael P. McCarthy,Patricia A. Bradford,Mark T. Esser +11 more
TL;DR: It is demonstrated that Hla is conserved in diverse S. aureus isolates from around the world and is an attractive target for prophylactic monoclonal antibody (MAb) or vaccine development.
54
Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates
David E. Tabor,Vaheh Oganesyan,Ashley E. Keller,Li Yu,Robert E. McLaughlin,E Song,Paul Warrener,Kim Rosenthal,Mark T. Esser,Y Qi,Alexey Ruzin,C. K. Stover,Antonio DiGiandomenico +12 more
TL;DR: Psl and PcrV are highly prevalent in global clinical isolates, suggesting MEDI3902 can mediate broad coverage against P. aeruginosa.
51
Characterization of Alpha-Toxin hla Gene Variants, Alpha-Toxin Expression Levels, and Levels of Antibody to Alpha-Toxin in Hemodialysis and Postsurgical Patients with Staphylococcus aureus Bacteremia
Batu K. Sharma-Kuinkel,Yuling Wu,David E. Tabor,Hoyin Mok,Bret R. Sellman,Amy Jenkins,Li Yu,Hasan S. Jafri,Thomas H. Rude,Felicia Ruffin,Wiley A. Schell,Lawrence P. Park,Qin Yan,Joshua T. Thaden,Julia A. Messina,Vance G. Fowler,Mark T. Esser +16 more
TL;DR: Data demonstrate that alpha-toxin is highly conserved in clinical S. aureus isolates, and all genotypic variants were susceptible to a neutralizing monoclonal antibody in clinical development (MEDI4893).
48